CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Takeda Pharmaceuticals U.S.A., Inc. v. Scilex Pharmaceuticals Inc.

1:23-cv-01264

Overview

Case Number 1:23-cv-01264
Filing Date 2023-11-06
Status Terminated
Termination Date 2024-05-03
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Scilex Holding Company NPE (Individual / Inventor)

Represented By

5 Attorneys Listed

William R. Zimmerman

Email: bill.zimmerman@knobbe.com

Megan C. Haney

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, McLaughlin & Hall, P.A., DE

Joseph M. Reisman

Email: joseph.reisman@knobbe.com

Ashley C. Morales

Email: ashley.morales@knobbe.com

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Scilex Pharmaceuticals Inc. Operating Company

Represented By

5 Attorneys Listed

William R. Zimmerman

Email: bill.zimmerman@knobbe.com

Megan C. Haney

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, McLaughlin & Hall, P.A., DE

Joseph M. Reisman

Email: joseph.reisman@knobbe.com

Ashley C. Morales

Email: ashley.morales@knobbe.com

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

Takeda Pharmaceuticals U.S.A., Inc. Operating Company

Represented By

4 Attorneys Listed

Porter F. Fleming

Email: pfleming@haugpartners.com

Edgar H. Haug

Email: ehaug@haugpartners.com

Thatcher A. Rahmeier

Faegre Drinker Biddle & Reath LLP

Tel: +1 (302) 467-4211
Fax: +1 (302) 467-4201

222 Delaware Avenue, Suite 1410

Francis DiGiovanni

Faegre Drinker Biddle & Reath LLP

Tel: +1 (302) 467-4266
Fax: +1 (302) 467-4201

222 Delaware Avenue, Suite 1410

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

6 Patents

There are 6 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7619004
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2008-12-03
Issued: 2009-11-17
Active (2.0 yrs remaining)
Expires: 2028-12-03
US7820681
Methods for concomitant administration of colchicine and a second active agent
Filed: 2009-02-17
Issued: 2010-10-26
Active (2.2 yrs remaining)
Expires: 2029-02-17
US7964648
Methods for concomitant administration of colchicine and a second active agent
Filed: 2010-01-15
Issued: 2011-06-21
Active (3.2 yrs remaining)
Expires: 2030-01-15
US8093297
Methods for concomitant administration of colchicine and a second active agent
Filed: 2011-04-22
Issued: 2012-01-10
Active (4.4 yrs remaining)
Expires: 2031-04-22
US8097655
Methods for concomitant administration of colchicine and macrolide antibiotics
Filed: 2011-05-17
Issued: 2012-01-17
Active (4.5 yrs remaining)
Expires: 2031-05-17

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(44 total)
Court Order

MOTION for Confidential Treatment of the Complaint and its Exhibit L - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Proposed Order)(jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023)

Entry #1 • 2023-11-06
1
Court Order

MOTION for Confidential Treatment of the Complaint and its Exhibit L - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Proposed Order)(jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023)

Entry #1 • 2023-11-06
2
Pleading / Complaint

DECLARATION of Thatcher A. Rahmeier re 1 MOTION for Confidential Treatment of the Complaint and its Exhibit L, by Takeda Pharmaceuticals U.S.A., Inc. (jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023)

Entry #2 • 2023-11-06
1
Pleading / Complaint

[SEALED] Complaint filed against Scilex Holding Company, Scilex Pharmaceuticals Inc. (Filing fee $ 402, receipt number ADEDC-4266719) - filed by Takeda Pharmaceuticals U.S.A., Inc. (Attachments: # 1 Exhibits A-K, # 2 Exhibit L, # 3 Civil Cover Sheet)(jfm) Modified on 11/7/2023 (nms). (Entered: 11/06/2023)

Entry #3 • 2023-11-06
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: September 25, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/25/2026. (jfm) (Entered: 11/06/2023)

Entry #4 • 2023-11-06
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc